The estimated Net Worth of Roelof Rongen is at least $12.5 Million dollars as of 8 September 2017. Roelof Rongen owns over 5,000 units of Matinas Biopharma Inc stock worth over $12,511,836 and over the last 7 years Roelof sold MTNB stock worth over $0.
Sign up
Roelof Rongen MTNB stock SEC Form 4 insiders trading
Roelof has made over 1 trades of the Matinas Biopharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Roelof bought 5,000 units of MTNB stock worth $6,800 on 8 September 2017.
The largest trade Roelof's ever made was buying 5,000 units of Matinas Biopharma Inc stock on 8 September 2017 worth over $6,800. On average, Roelof trades about 5,000 units every 0 days since 2017. As of 8 September 2017 Roelof still owns at least 3,539,416 units of Matinas Biopharma Inc stock.
You can see the complete history of Roelof Rongen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Roelof Rongen's mailing address?
Roelof's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER, NJ, 07921.
Insiders trading at Matinas Biopharma Inc
Over the last 8 years, insiders at Matinas Biopharma Inc have traded over $0 worth of Matinas Biopharma Inc stock and bought 1,157,037 units worth $1,139,222 . The most active insiders traders include Patrick G Lepore, Adam K Stern und James S Scibetta. On average, Matinas Biopharma Inc executives and independent directors trade stock every 40 days with the average trade being worth of $187,938. The most recent stock trade was executed by Adam K Stern on 21 August 2020, trading 20,000 units of MTNB stock currently worth $16,600.
What does Matinas Biopharma Inc do?
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
What does Matinas Biopharma Inc's logo look like?
Complete history of Roelof Rongen stock trades at Matinas Biopharma Inc
Matinas Biopharma Inc executives and stock owners
Matinas Biopharma Inc executives and other stock owners filed with the SEC include:
-
Jerome Jabbour,
President, Chief Executive Officer, Director -
Keith Kucinski,
Chief Financial Officer -
James Ferguson,
Chief Medical Officer -
Jerome D. Jabbour J.D.,
Co-Founder, CEO, Pres & Director -
Theresa Matkovits,
Chief Development Officer -
Dr. James J. Ferguson FACC, M.D.,
Chief Medical Officer -
Dr. Theresa Matkovits Ph.D.,
Chief Devel. Officer -
Raphael Mannino,
Chief Scientific Officer -
Ian Cooney,
Director ,Investor Relations & Corporate Development -
Matthew Wikler,
Independent Director -
James Scibetta,
Independent Director -
Natasha Giordano,
Independent Director -
Eric Ende,
Independent Director -
Patrick LePore,
Independent Vice Chairman of the board -
Herbert Conrad,
Independent Chairman of the Board -
Thomas J. Hoover M.B.A.,
Chief Bus. Officer -
Frank Calamusa,
Exec. Director and Head of Manufacturing & Supply Chain -
Dr. Raphael J. Mannino Ph.D.,
Chief Scientific Officer -
Dr. Hui Liu M.B.A., Ph.D.,
Chief Technology Officer -
Keith A. Kucinski CPA, M.B.A.,
Chief Financial Officer -
Adam K Stern,
Director -
Dominick Di Paolo,
Senior VP of Compliance -
Gary Gaglione,
Chief Financial Officer -
Roelof Rongen,
Chief Executive Officer -
Jennifer Gjg Life Sciences,...,
-
Stefano Ferrari,
Director -
Hui Liu,
Chief Technology Officer -
Kathryn Penkus Corzo,
Director -
Thomas Hoover,
Chief Business Officer